Top

Published in:

Open Access 01-09-2012 | Original Contribution

Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation

Authors: K. Hoetzenecker, A. Assinger, M. Lichtenauer, M. Mildner, T. Schweiger, P. Starlinger, A. Jakab, E. Berényi, N. Pavo, M. Zimmermann, C. Gabriel, C. Plass, M. Gyöngyösi, I. Volf, H. J. Ankersmit

Published in: Basic Research in Cardiology | Issue 5/2012

Abstract

Although epicardial blood flow can be restored by an early intervention in most cases, a lack of adequate reperfusion at the microvascular level is often a limiting prognostic factor of acute myocardial infarction (AMI). Our group has recently found that paracrine factors secreted from apoptotic peripheral blood mononuclear cells (APOSEC) attenuate the extent of myocardial injury. The aim of this study was to determine the influence of APOSEC on microvascular obstruction (MVO) in a porcine AMI model. A single dose of APOSEC was intravenously injected in a closed chest reperfused infarction model. MVO was determined by magnetic resonance imaging and cardiac catheterization. Role of platelet function and vasodilation were monitored by means of ELISA, flow cytometry, aggregometry, western blot and myographic experiments in vitro and in vivo. Treatment of AMI with APOSEC resulted in a significant reduction of MVO. Platelet activation markers were reduced in plasma samples obtained during AMI, suggesting an anti-aggregatory capacity of APOSEC. This finding was confirmed by in vitro tests showing that activation and aggregation of both porcine and human platelets were significantly impaired by co-incubation with APOSEC, paralleled by vasodilator-stimulated phosphoprotein (VASP)-mediated inhibition of platelets. In addition, APOSEC evidenced a significant vasodilatory capacity on coronary arteries via p-eNOS and iNOS activation. Our data give first evidence that APOSEC reduces the extent of MVO during AMI, and suggest that modulation of platelet activation and vasodilation in the initial phase after myocardial infarction contributes to the improved long-term outcome in APOSEC treated animals.

Available only for authorised users

Adlbrecht C, Bonderman D, Plass C, Jakowitsch J, Beran G, Sperker W, Siostrzonek P, Glogar D, Maurer G, Lang IM (2007) Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb Haemost 97:642–649 [pii: 07040642]PubMed

Albert TS, Kim RJ, Judd RM (2006) Assessment of no-reflow regions using cardiac MRI. Basic Res Cardiol 101:383–390. doi:10.1007/s00395-006-0617-0 PubMedCrossRef

Angoulvant D, Ivanes F, Ferrera R, Matthews PG, Nataf S, Ovize M (2011) Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury. J Heart Lung Transpl 30:95–102. doi:10.1016/j.healun.2010.08.023 CrossRef

Ankersmit HJ, Hoetzenecker K, Dietl W, Soleiman A, Horvat R, Wolfsberger M, Gerner C, Hacker S, Mildner M, Moser B, Lichtenauer M, Podesser BK (2009) Irradiated cultured apoptotic peripheral blood mononuclear cells regenerate infarcted myocardium. Eur J Clin Invest 39:445–456. doi:10.1111/j.1365-2362.2009.02111.x PubMedCrossRef

Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44:E1–E211. doi:10.1016/j.jacc.2004.07.014 PubMedCrossRef

Assinger A, Schmid W, Eder S, Schmid D, Koller E, Volf I (2008) Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett 582:778–784. doi:10.1016/j.febslet.2008.02.001 PubMedCrossRef

Barrabes JA, Garcia-Dorado D, Mirabet M, Inserte J, Agullo L, Soriano B, Massaguer A, Padilla F, Lidon RM, Soler–Soler J (2005) Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J Am Coll Cardiol 45:293–299. doi:10.1016/j.jacc.2004.09.068 PubMedCrossRef

Barrabes JA, Mirabet M, Agullo L, Figueras J, Pizcueta P, Garcia-Dorado D (2007) Platelet deposition in remote cardiac regions after coronary occlusion. Eur J Clin Invest 37:939–946. doi:10.1111/j.1365-2362.2007.01883.x PubMedCrossRef

Bekkers SC, Yazdani SK, Virmani R, Waltenberger J (2010) Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 55:1649–1660. doi:10.1016/j.jacc.2009.12.037 PubMedCrossRef

10.

Bishop SP, White FC, Bloor CM (1976) Regional myocardial blood flow during acute myocardial infarction in the conscious dog. Circ Res 38:429–438PubMedCrossRef

11.

Bolli R, Chugh AR, D’Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P (2011) Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378:1847–1857. doi:10.1016/S0140-6736(11)61590-0 PubMedCrossRef

12.

Claeys MJ, Bosmans J, Veenstra L, Jorens P, De Raedt H, Vrints CJ (1999) Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. Circulation 99:1972–1977PubMedCrossRef

13.

Di Santo S, Yang Z, Wyler von Ballmoos M, Voelzmann J, Diehm N, Baumgartner I, Kalka C (2009) Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One 4:e5643. doi:10.1371/journal.pone.0005643 PubMedCrossRef

14.

Fazel S, Cimini M, Chen L, Li S, Angoulvant D, Fedak P, Verma S, Weisel RD, Keating A, Li RK (2006) Cardioprotective c-kit⁺ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 116:1865–1877. doi:10.1172/JCI27019 PubMedCrossRef

15.

Fazel SS, Chen L, Angoulvant D, Li SH, Weisel RD, Keating A, Li RK (2008) Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury. FASEB J 22:930–940. doi:10.1096/fj.07-8636com PubMedCrossRef

16.

Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B (2004) Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110:1392–1397. doi:10.1161/01.CIR.0000141575.92958.9C PubMedCrossRef

17.

Gawaz M (2004) Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 61:498–511. doi:10.1016/j.cardiores.2003.11.036 PubMedCrossRef

18.

Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E (1996) TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93:879–888PubMedCrossRef

19.

Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11:367–368. doi:10.1038/nm0405-367 PubMedCrossRef

20.

Gnecchi M, Zhang Z, Ni A, Dzau VJ (2008) Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 103:1204–1219. doi:10.1161/CIRCRESAHA.108.176826 PubMedCrossRef

21.

Golino P, Ashton JH, Buja LM, Rosolowsky M, Taylor AL, McNatt J, Campbell WB, Willerson JT (1989) Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators. Circulation 79:154–166PubMedCrossRef

22.

Gyongyosi M, Lang I, Dettke M, Beran G, Graf S, Sochor H, Nyolczas N, Charwat S, Hemetsberger R, Christ G, Edes I, Balogh L, Krause KT, Jaquet K, Kuck KH, Benedek I, Hintea T, Kiss R, Preda I, Kotevski V, Pejkov H, Zamini S, Khorsand A, Sodeck G, Kaider A, Maurer G, Glogar D (2009) Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med 6:70–81. doi:10.1038/ncpcardio1388 PubMedCrossRef

23.

Halkos ME, Zhao ZQ, Kerendi F, Wang NP, Jiang R, Schmarkey LS, Martin BJ, Quyyumi AA, Few WL, Kin H, Guyton RA, Vinten-Johansen J (2008) Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Res Cardiol 103:525–536. doi:10.1007/s00395-008-0741-0 PubMedCrossRef

24.

Henriques JP, Zijlstra F, Vant Hof AW, de Boer MJ, Dambrink JH, Gosselink M, Hoorntje JC, Suryapranata H (2003) Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 107:2115–2119. doi:10.1161/01.CIR.0000065221.06430.ED PubMedCrossRef

25.

Heusch G (2010) Adenosine and maximum coronary vasodilation in humans: myth and misconceptions in the assessment of coronary reserve. Basic Res Cardiol 105:1–5. doi:10.1007/s00395-009-0074-7 PubMedCrossRef

26.

Heusch G (2011) SCIPIO brings new momentum to cardiac cell therapy. Lancet 378:1827–1828. doi:10.1016/S0140-6736(11)61648-6 PubMedCrossRef

27.

Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118:1915–1919. doi:10.1161/CIRCULATIONAHA.108.805242 PubMedCrossRef

28.

Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, Erbel R (2009) Coronary microembolization: from bedside to bench and back to bedside. Circulation 120:1822–1836. doi:10.1161/CIRCULATIONAHA.109.888784 PubMedCrossRef

29.

Heusch G, Post H, Michel MC, Kelm M, Schulz R (2000) Endogenous nitric oxide and myocardial adaptation to ischemia. Circ Res 87:146–152PubMedCrossRef

30.

Hoffmann R, Haager P, Arning J, Christott P, Radke P, Blindt R, Ortlepp J, Lepper W, Hanrath P (2003) Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. Am J Cardiol 92:1015–1019 [pii: S0002914903010324]PubMedCrossRef

31.

Ito H (2006) No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 3:499–506. doi:10.1038/ncpcardio0632 PubMedCrossRef

32.

Kimura A, Ishikawa K, Ogawa I (1998) Myocardial salvage by reperfusion 12 h after coronary ligation in dogs. Jpn Circ J 62:294–298PubMedCrossRef

33.

Klein LW, Kern MJ, Berger P, Sanborn T, Block P, Babb J, Tommaso C, Hodgson JM, Feldman T (2003) Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 60:194–201. doi:10.1002/ccd.10620 PubMedCrossRef

34.

Kleinbongard P, Bose D, Baars T, Mohlenkamp S, Konorza T, Schoner S, Elter-Schulz M, Eggebrecht H, Degen H, Haude M, Levkau B, Schulz R, Erbel R, Heusch G (2011) Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary by pass grafts and its pharmacological attenuation. Circ Res 108:344–352. doi:10.1161/CIRCRESAHA.110.235713 PubMedCrossRef

35.

Kohler D, Straub A, Weissmuller T, Faigle M, Bender S, Lehmann R, Wendel HP, Kurz J, Walter U, Zacharowski K, Rosenberger P (2011) Phosphorylation of vasodilator-stimulated phosphoprotein prevents platelet-neutrophil complex formation and dampens myocardial ischemia-reperfusion injury. Circulation 123:2579–2590. doi:10.1161/CIRCULATIONAHA.110.014555 PubMedCrossRef

36.

Korf-Klingebiel M, Kempf T, Sauer T, Brinkmann E, Fischer P, Meyer GP, Ganser A, Drexler H, Wollert KC (2008) Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur Heart J 29:2851–2858. doi:10.1093/eurheartj/ehn456 PubMedCrossRef

37.

Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria AN (2004) Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 43:276–283 [pii: S0735109703014323]PubMedCrossRef

38.

Lichtenauer M, Mildner M, Baumgartner A, Hasun M, Werba G, Beer L, Altmann P, Roth G, Gyongyosi M, Podesser BK, Ankersmit HJ (2011) Intravenous and intramyocardial injection of apoptotic white blood cell suspensions prevents ventricular remodelling by increasing elastin expression in cardiac scar tissue after myocardial infarction. Basic Res Cardiol 106:645–655. doi:10.1007/s00395-011-0173-0 PubMedCrossRef

39.

Lichtenauer M, Mildner M, Hoetzenecker K, Zimmermann M, Podesser BK, Sipos W, Berenyi E, Dworschak M, Tschachler E, Gyongyosi M, Ankersmit HJ (2011) Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical study. Basic Res Cardiol 106:1283–1297. doi:10.1007/s00395-011-0224-6 PubMedCrossRef

40.

Lodi D, Iannitti T, Palmieri B (2011) Stem cells in clinical practice: applications and warnings. J Exp Clin Cancer Res 30:9. doi:10.1186/1756-9966-30-9 PubMedCrossRef

41.

Madonna R, Rokosh G, De Caterina R, Bolli R (2010) Hepatocyte growth factor/Met gene transfer in cardiac stem cells—potential for cardiac repair. Basic Res Cardiol 105:443–452. doi:10.1007/s00395-010-0102-7 PubMedCrossRef

42.

Meneveau N, Deschaseaux F, Seronde MF, Chopard R, Schiele F, Jehl J, Tiberghien P, Bassand JP, Kantelip JP, Davani S (2011) Presence of endothelial colony-forming cells is associated with reduced microvascular obstruction limiting infarct size and left ventricular remodelling in patients with acute myocardial infarction. Basic Res Cardiol 106:1397–1410. doi:10.1007/s00395-011-0220-x PubMedCrossRef

43.

Michelson AD, Furman MI (1999) Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 6:342–348PubMedCrossRef

44.

Milavetz JJ, Giebel DW, Christian TF, Schwartz RS, Holmes DR Jr, Gibbons RJ (1998) Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol 31:1246–1251 [pii: S0735109798000886]PubMedCrossRef

45.

Mildner M, Eckhart L, Lengauer B, Tschachler E (2002) Hepatocyte growth factor/scatter factor inhibits UVB-induced apoptosis of human keratinocytes but not of keratinocyte-derived cell lines via the phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem 277:14146–14152. doi:10.1074/jbc.M110687200 PubMedCrossRef

46.

Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344:1895–1903. doi:10.1056/NEJM200106213442503 PubMedCrossRef

47.

Oerlemans MI, Goumans MJ, van Middelaar B, Clevers H, Doevendans PA, Sluijter JP (2010) Active Wnt signaling in response to cardiac injury. Basic Res Cardiol 105:631–641. doi:10.1007/s00395-010-0100-9 PubMedCrossRef

48.

Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P (2001) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 98:10344–10349. doi:10.1073/pnas.181177898 PubMedCrossRef

49.

Ortiz-Perez JT, Meyers SN, Lee DC, Kansal P, Klocke FJ, Holly TA, Davidson CJ, Bonow RO, Wu E (2007) Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. Eur Heart J 28:1750–1758. doi:10.1093/eurheartj/ehm212 PubMedCrossRef

50.

Pitarys CJ 2nd, Virmani R, Vildibill HD Jr, Jackson EK, Forman MB (1991) Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 83:237–247PubMedCrossRef

51.

Reffelmann T, Kloner RA (2006) The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 101:359–372. doi:10.1007/s00395-006-0615-2 PubMedCrossRef

52.

Sandstedt J, Jonsson M, Lindahl A, Jeppsson A, Asp J (2010) C-kit⁺ CD45-cells found in the adult human heart represent a population of endothelial progenitor cells. Basic Res Cardiol 105:545–556. doi:10.1007/s00395-010-0088-1 PubMedCrossRef

53.

Sanganalmath SK, Abdel-Latif A, Bolli R, Xuan YT, Dawn B (2011) Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond. Basic Res Cardiol 106:709–733. doi:10.1007/s00395-011-0183-y PubMedCrossRef

54.

Schafer A, Fraccarollo D, Werner L, Bauersachs J (2010) Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol Res 62:432–438. doi:10.1016/j.phrs.2010.06.008 PubMedCrossRef

55.

Seal JB, Gewertz BL (2005) Vascular dysfunction in ischemia-reperfusion injury. Ann Vasc Surg 19:572–584. doi:10.1007/s10016-005-4616-7 PubMedCrossRef

56.

See F, Seki T, Psaltis PJ, Sondermeijer HP, Gronthos S, Zannettino AC, Govaert KM, Schuster MD, Kurlansky PA, Kelly DJ, Krum H, Itescu S (2011) Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. J Cell Mol Med 15:2117–2129. doi:10.1111/j.1582-4934.2010.01241.x PubMedCrossRef

57.

Skyschally A, Leineweber K, Gres P, Haude M, Erbel R, Heusch G (2006) Coronary microembolization. Basic Res Cardiol 101:373–382. doi:10.1007/s00395-006-0616-1 PubMedCrossRef

58.

Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker K, Gruenberger B, Gruenberger T, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C (2010) Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. J Thromb Haemost 8:1809–1819. doi:10.1111/j.1538-7836.2010.03908.x PubMedCrossRef

59.

Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D’Agostino RB, Levy D, Kannel WB, Vasan RS (2008) Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 118:2057–2062. doi:10.1161/CIRCULATIONAHA.108.784215 PubMedCrossRef

60.

Villari B, Ambrosio G, Golino P, Ragni M, Focaccio A, Tritto I, Salvatore M, Chiariello M (1993) The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. Am Heart J 125:11–23PubMedCrossRef

61.

Wollert KC, Drexler H (2010) Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol 7:204–215. doi:10.1038/nrcardio.2010.1 PubMedCrossRef

62.

Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H (2004) Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364:141–148. doi:10.1016/S0140-6736(04)16626-9 PubMedCrossRef

63.

Wu J, Li J, Zhang N, Zhang C (2011) Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation. Basic Res Cardiol 106:317–324. doi:10.1007/s00395-011-0168-x PubMedCrossRef

64.

Xu Y, Huo Y, Toufektsian MC, Ramos SI, Ma Y, Tejani AD, French BA, Yang Z (2006) Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 290:H692–H699. doi:10.1152/ajpheart.00634.2005 PubMedCrossRef

Title: Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation
Authors: K. Hoetzenecker
A. Assinger
M. Lichtenauer
M. Mildner
T. Schweiger
P. Starlinger
A. Jakab
E. Berényi
N. Pavo
M. Zimmermann
C. Gabriel
C. Plass
M. Gyöngyösi
I. Volf
H. J. Ankersmit
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: Basic Research in Cardiology / Issue 5/2012
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-012-0292-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

Chronic creatine kinase deficiency eventually leads to congestive heart failure, but severity is dependent on genetic background, gender and age

Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation

Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients

Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging

Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: results of a comprehensive analysis of determinants of infarct size in 1,074 mice

Transcriptional regulation of Nox4 by histone deacetylases in human endothelial cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page